Intarcia Therapeutics, Inc.

Intarcia Therapeutics, Inc. company information, Employees & Contact Information

Explore related pages

Intarcia Therapeutics, Inc. email format Intarcia Therapeutics, Inc. management contacts

Related company profiles:

We operate with a “No Analog” mindset—continually pushing boundaries, navigating new terrain and unleashing fresh thinking. We are committed to seeking better outcomes which compels us to ask questions that have not been asked before or remain unresolved. We are driven by a desire to create meaningful impact across business, health and society to ease the burden on people living with chronic diseases. Intarcia is a rapidly emerging biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease. Our cross-disciplinary teams include forward-thinking scientists and entrepreneurs collaborating in a fast-paced environment redefining the future of medicine.

Company Details

Employees
69
Founded
-
Address
One Marina Park Drive, Suite 1300,united States
Phone
617-936-2500
Email
bu****@****cia.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Website
intarcia.com
HQ
Boston, MA
Competitors
Sangamo Therapeutics, Inc., Genentech, Allogene Therapeutics, Biogen, Corcept Therapeutics, Ipsen, Novartis, i2o Therapeutics, Akebia Therapeutics, Oliva Therapeutics, LLC.
Looking for a particular Intarcia Therapeutics, Inc. employee's phone or email?

Intarcia Therapeutics, Inc. Questions

News

Intarcia, a former biotech unicorn, gets new life with startup deal - BioPharma Dive

Intarcia, a former biotech unicorn, gets new life with startup deal BioPharma Dive

Intarcia Therapeutics Provides Regulatory Update - FDA Accepts Resubmitted New Drug Application For ITCA 650 - PR Newswire

Intarcia Therapeutics Provides Regulatory Update - FDA Accepts Resubmitted New Drug Application For ITCA 650 PR Newswire

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: - American Heart Association Journals

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: American Heart Association Journals

Intarcia And Servier Sign Ex-U.S. Partnership For ITCA 650 In Diabetes; Intarcia Retains Independence & Full Control Of The U.S. & Japan - PR Newswire

Intarcia And Servier Sign Ex-U.S. Partnership For ITCA 650 In Diabetes; Intarcia Retains Independence & Full Control Of The U.S. & Japan PR Newswire

Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes - PR Newswire

Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes PR Newswire

Intarcia Therapeutics Announces Upcoming Presentation at 35th Annual J.P. Morgan Healthcare Conference - PR Newswire

Intarcia Therapeutics Announces Upcoming Presentation at 35th Annual J.P. Morgan Healthcare Conference PR Newswire

Intarcia Appoints Anthony Hurley as VP, Global Commercial Manufacturing and Operations, Reporting To Chairman & CEO Kurt Graves - PR Newswire

Intarcia Appoints Anthony Hurley as VP, Global Commercial Manufacturing and Operations, Reporting To Chairman & CEO Kurt Graves PR Newswire

Intarcia Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of ITCA 650 in Type 2 Diabetes - PR Newswire

Intarcia Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of ITCA 650 in Type 2 Diabetes PR Newswire

Intarcia Announces Branding of the Medici Drug Delivery System™ -- A Platform of Technologies Key to Advancing its Pipeline of Once-Yearly Peptide and Antibody Fragment-Based Therapeutics in Poorly Controlled Chronic Diseases - PR Newswire

Intarcia Announces Branding of the Medici Drug Delivery System™ -- A Platform of Technologies Key to Advancing its Pipeline of Once-Yearly Peptide and Antibody Fragment-Based Therapeutics in Poorly Controlled Chronic Diseases PR Newswire

Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes - PR Newswire

Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes PR Newswire

Intarcia Appoints Dr. John Yee into New Role of VP, Global Medical Affairs, Safety and Operations, Reporting Directly to Chairman & CEO Kurt Graves - PR Newswire

Intarcia Appoints Dr. John Yee into New Role of VP, Global Medical Affairs, Safety and Operations, Reporting Directly to Chairman & CEO Kurt Graves PR Newswire

Intarcia Therapeutics Names Emad Rizk, MD, To Board Of Directors - PR Newswire

Intarcia Therapeutics Names Emad Rizk, MD, To Board Of Directors PR Newswire

Intarcia Announces Appointment Of Dr. Sunita Zalani As Vice President, Global Head Of Regulatory Affairs And Quality - PR Newswire

Intarcia Announces Appointment Of Dr. Sunita Zalani As Vice President, Global Head Of Regulatory Affairs And Quality PR Newswire

Companies like Intarcia Therapeutics, Inc.

Sangamo Therapeutics, Inc. logo - Similar company to Intarcia Therapeutics, Inc.

Sangamo Therapeutics...

267
Genentech logo - Similar company to Intarcia Therapeutics, Inc.

Genentech

18.23K
Biogen logo - Similar company to Intarcia Therapeutics, Inc.

Biogen

7.60K
Akebia Therapeutics logo - Similar company to Intarcia Therapeutics, Inc.

Akebia Therapeutics

268
Novartis logo - Similar company to Intarcia Therapeutics, Inc.

Novartis

79.78K
i2o Therapeutics logo - Similar company to Intarcia Therapeutics, Inc.

I2O Therapeutics

6
Corcept Therapeutics logo - Similar company to Intarcia Therapeutics, Inc.

Corcept Therapeutics

634
Oliva Therapeutics, LLC logo - Similar company to Intarcia Therapeutics, Inc.

Oliva Therapeutics, Llc

3
Allogene Therapeutics logo - Similar company to Intarcia Therapeutics, Inc.

Allogene Therapeutics

222
Ipsen logo - Similar company to Intarcia Therapeutics, Inc.

Ipsen

6.38K

Top Intarcia Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant